Acyclic Carbon To Carbon Unsaturation Patents (Class 514/733)
-
Patent number: 8080527Abstract: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.Type: GrantFiled: July 26, 2010Date of Patent: December 20, 2011Assignee: The Regents of the University of CaliforniaInventor: Michael David
-
Publication number: 20110280909Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.Type: ApplicationFiled: January 29, 2010Publication date: November 17, 2011Inventor: Kambiz Thomas Moazed
-
Publication number: 20110281826Abstract: The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.Type: ApplicationFiled: May 31, 2011Publication date: November 17, 2011Inventors: Uh-Hyun Kim, Ho-Jeong Kwon, Mie-Jae Im, Seon-Young Kim, Kwang-Hyun Park, So-Young Rah, Tae-Sik Nam, Byung-Ju Kim, Gul Rukhsana
-
Publication number: 20110280964Abstract: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal.Type: ApplicationFiled: April 21, 2011Publication date: November 17, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Josef Miller, Colleen LePrell, Jochen Schacht, Diane Prieskorn
-
Publication number: 20110281957Abstract: Methods and formulations for increasing the water solubility and/or bioavailability of resveratrol are disclosed. The formulations may be employed to treat a disease states, including cancer.Type: ApplicationFiled: November 19, 2009Publication date: November 17, 2011Applicant: Lipoprotein Technologies, Inc.Inventor: Eric Kuhrts
-
Publication number: 20110274746Abstract: The present invention provides therapeutic liposomes and methods for producing and using the same. In particular, therapeutic liposomes of the invention comprise phospholipids comprising C16-C22 fatty acid ester moieties. In some embodiments, these therapeutic liposomes are used in assisting delivery of an active compound, e.g., a drug and/or a nutraceutical, to a subject. In some embodiments, compositions of the invention have synergistic therapeutic effect.Type: ApplicationFiled: May 10, 2011Publication date: November 10, 2011Inventors: Michael A. Schmidt, Joseph J. Miller
-
Publication number: 20110257256Abstract: The present invention is directed to the use of at least one cannabinoid in the manufacture of a medicament for use in treating or preventing or in the manufacture of a dietary supplement for preventing a disease or condition benefiting from a reduced activity of the enzyme indoleamine 2,3-dioxygenase (IDO). The disease or condition to be treated or prevented is preferably selected from cognitive impairment or any kind of dementia.Type: ApplicationFiled: July 31, 2009Publication date: October 20, 2011Applicant: BIONORIA RESEARCH GMBHInventors: Dietmar Fuchs, Marcel Jenny, Eberhard Pirich
-
Publication number: 20110251146Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.Type: ApplicationFiled: June 21, 2011Publication date: October 13, 2011Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTDInventors: Greg DAVEY, Albert Zorko ABRAM
-
Publication number: 20110223269Abstract: An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a form of eye drops or eye washes, oral preparation, etc. An agent for treating eye diseases which has excellent treatment effects, reduced in side action can be provided.Type: ApplicationFiled: March 2, 2011Publication date: September 15, 2011Inventor: Shinseiro OKAMOTO
-
Publication number: 20110218158Abstract: Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.Type: ApplicationFiled: September 22, 2009Publication date: September 8, 2011Inventors: Reuben S. Harris, Ming Li
-
Publication number: 20110212173Abstract: There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof for the treatment or alleviation of depression. More particularly, there is described an abuse resistant pharmaceutical composition for the treatment of inter alia, depression and controlled release pharmaceutical compositions of related thereto.Type: ApplicationFiled: June 17, 2009Publication date: September 1, 2011Applicant: e-Therapeutics PleInventors: Malcolm Philip Young, Olusola Clement Idowu, Philip McKeown
-
Publication number: 20110212199Abstract: An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a form of eye drops or eye washes, oral preparation, etc. An agent for treating eye diseases which has excellent treatment effects, reduced in side action can be provided.Type: ApplicationFiled: March 2, 2011Publication date: September 1, 2011Inventor: Shinseiro Okamoto
-
Publication number: 20110212200Abstract: An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a form of eye drops or eye washes, oral preparation, etc. An agent for treating eye diseases which has excellent treatment effects, reduced in side action can be provided.Type: ApplicationFiled: March 2, 2011Publication date: September 1, 2011Inventor: Shinseiro OKAMOTO
-
Publication number: 20110195039Abstract: A method of treating hair comprising applying a hair building solid agent for use on or with one or more of hair, skin and hair building solids for altering and/or maintaining the electrostatic charge of the hair and/or skin such that it has a substantially negative polarity. The method further comprises applying hair building solids to hair before and/or during and/or after applying the hair building solid agent. The hair building solid agent is applied as a spray on to the hair and/or skin and/or hair building solid.Type: ApplicationFiled: February 11, 2011Publication date: August 11, 2011Applicant: PANGAEA LABORATORIES LTD.Inventor: Elliot Isaacs
-
Publication number: 20110196383Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in a patient's blood vessels is provided. A chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive substance is administered at sites of the plaques. The chemical composition comprises one or more of d-limonene, propylene glycol, octanoic acid, 2-octane, glycerine, acetylsalicylic acid, acetic acid, omega-3 fatty acids, ethanol, methanol, ezetimibe, rosuvastatin, resveratrol, lactic acid, gluconic acid, chloroform, carbon disulfide, dichloromethane, toluene, lauryldimethyl hydroxysultaine, and any combination thereof. The chemical composition enables modification of plaques by altering their composition. The modification comprises partial dissolution, complete dissolution, or elimination of the plaques, and makes the plaques amenable to different forms of plaque treatment. The modified plaques are eliminated from the patient's body.Type: ApplicationFiled: April 15, 2011Publication date: August 11, 2011Inventors: Kusai Saadeldin Aziz, Gary Michael Saxton
-
Publication number: 20110189288Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: March 3, 2011Publication date: August 4, 2011Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang, Diana Shu-Lian Chow, Roland A. Ako
-
Patent number: 7989486Abstract: The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3?-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV.Type: GrantFiled: December 30, 2005Date of Patent: August 2, 2011Assignee: Bioresponse, L.L.C.Inventor: Michael A. Zeligs
-
Publication number: 20110183016Abstract: The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, which form a film after application onto the scalp and/or the hair, which compositions are useful for delivery of actives onto the scalp surface and/or onto the hair.Type: ApplicationFiled: February 4, 2011Publication date: July 28, 2011Applicant: POLICHEM SAInventors: Federico Mailland, Emanuela Mura
-
Publication number: 20110144125Abstract: The disclosure describes an animal model for simulating cardiac arrhythmia. Methods of discovering new anti-arrhythmia drugs using the model are described. Novel anti-arrhythmia agents are provided, as are pharmaceutical compositions made from the agents. Methods of inhibiting spontaneous mechanical activity in myocardially-derived biological systems, and methods of treating and preventing cardiac arrhythmia based on novel anti-arrhythmia agents are described. Kits for performing the above methods are also described.Type: ApplicationFiled: August 14, 2009Publication date: June 16, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventor: Paul Wolkowicz
-
Publication number: 20110142899Abstract: SUMMARY The present invention refers to new active nanocomposite materials, comprising a matrix and additives. The present invention also describes a process for obtaining these nanocomposite materials and their use in various industry sectors.Type: ApplicationFiled: June 25, 2009Publication date: June 16, 2011Applicant: NANOBIOMATTERS, S.L.Inventors: Jose Maria Lagaron Abello, Maria Antonieta Busolo Pons, Maria Eugenia Nunez Calzado
-
Publication number: 20110136901Abstract: The present invention discloses 4-nerolidylcatechol and its derivatives isolated from South American/Amazon plants (Pothomorphe species) and their potential use as therapeutical agent for treatment of malarial symptoms, including malarial patients resistant to traditional drugs. The present invention also discloses a method for producing 4-nerolidylcatechol and their derivatives.Type: ApplicationFiled: December 28, 2007Publication date: June 9, 2011Inventors: Ana Cristina Da Silva Pinto, Mà rcia Rùbia Silva Melo, Valter Ferreira De Andrade Neto, Francisco Célio Maia Chaves, Pedro Paulo Ribeiro Vieira, Adrian Martin Pohlit
-
Publication number: 20110130468Abstract: Compounds of the hydroxytolan family kill tumor cells, inhibit tumor growth and development, and are thus useful in method for treating a tumor or cancer in subjects in need thereof. These compounds are also active in preventing or treating a variety of skin diseases and conditions. The most preferred hydroxytolan compounds are 4,4?-dihydroxytolan. (KST-201), 4 hydroxy 4? trifluoromethyltolan or 4? hydroxy 4 trifluoromethyltolan (KST-213), 3,4?,5-trihydroxytolan or 3?,4,5?-trihydroxytolan (KST-301) and 3,3?,5,5?-tetrahydroxytolan (KST-401). The compounds and methods of using them alone and in combination with ascorbate and certain cyclic compounds to inhibit the development, growth or metastasis of tumor/cancer or preneoplastic cells, or to prevent or treat skin disorders in a subject are disclosed.Type: ApplicationFiled: June 20, 2008Publication date: June 2, 2011Applicant: Kent State UniversityInventor: Chun-Che Tsai
-
Publication number: 20110130469Abstract: The present invention relates to compositions and methods comprising resveratrol and uses thereof. Some embodiments include compositions and methods with increased bioavailability of resveratrol. Certain embodiments include compositions comprising resveratrol and a solubilizer. Particular embodiments include transmucosal delivery of resveratrol from the composition.Type: ApplicationFiled: November 29, 2010Publication date: June 2, 2011Applicant: WILMORE LABS L.L.CInventors: Otis L. Blanchard, Tina C. Blanchard
-
Publication number: 20110129426Abstract: An oral composition contains an enhanced antibacterial effective amount of an antioxidant and an extract of Magnolia.Type: ApplicationFiled: May 26, 2009Publication date: June 2, 2011Inventors: Minmin Tian, Michael W. Dodds, Michael J. Greenberg
-
Patent number: 7951845Abstract: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal.Type: GrantFiled: January 17, 2007Date of Patent: May 31, 2011Assignee: The Regents of the University of MichiganInventors: Josef Miller, Colleen LePrell, Jochen Schacht, Diane Prieskorn
-
Publication number: 20110123651Abstract: A nutritional beverage or drink is provided having resveratrol mixed with water, suspended in a liquid suspension system. One or more of quercetin, catechins, antioxidants, energy agents, sweeteners, preservatives, pH balancing ingredients, and coloring agents may also be included. A process is provided for preparing a dietary supplement drink in a liquid suspension, comprising mixing water in a suspension system with resveratrol. The process may also include adding one or more of quercetin, catechins, antioxidants, energy agents, sweeteners, preservatives, acidulants, and coloring agents. The nutritional beverage or drink may also be modified by using pure water that has nanosized water clusters therein, as well as mixing into the liquid suspension nanoparticles of resveratrol and/or one or more of the above ingredients to enhance the bioavailability of the ingredients. The compositions may be used to treat diseases and bodily malfunctions.Type: ApplicationFiled: May 20, 2010Publication date: May 26, 2011Inventors: Thomas E. Mower, Charles Jeffery Brady
-
Publication number: 20110110913Abstract: A method of inducing NAD+ synthesis in a subject. The method comprises administering to the subject a therapeutically effective amount of resveratrol or a functionally equivalent analogue or derivative thereof. NAD+ synthesis increases the activity of Poly(ADP-ribose) polymerase (PARP) enzymes and sirtuin enzymes. The PARP enzyme is PARP-1 or PARP-2 and the sirtuin enzyme is selected from the group consisting of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7.Type: ApplicationFiled: March 3, 2009Publication date: May 12, 2011Inventors: Ross Stewart Grant, Nady Braidy, Gilles Guillemin, George Smythe
-
Publication number: 20110052511Abstract: The present invention is directed to the use of a compound selected from the group consisting of ?-carotene, lutein, lycopene and ?-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including humans, for maintaining the respiratory function of the skin of animals including humans, for energizing the skin, maintaining and supporting the radiance and natural glow of the skin of animals including humans and for promoting a healthy appearance of the skin of animals including humans for preventing UV-A radiation-induced mtDNA mutagenesis in skin of animals including humans, as well as for the manufacture of a composition, preferably an orally applicable composition, for these uses and the corresponding methods.Type: ApplicationFiled: August 23, 2010Publication date: March 3, 2011Applicant: DSM IP ASSETS B.V.Inventors: Regina Goralczyk, Karin Wertz
-
Publication number: 20110046235Abstract: The present invention relates to uses of decarboxylated phenolic acid derived from chlorogenic acid of coffee as well as products comprising decarboxylated phenolic acid derived from chlorogenic acid of coffee, especially a coffee extract, and methods of producing such products. Coffee comprises chlorogenic acids, according to the invention these chlorogenic acids can be transformed into decarboxylated phenolic acids. The resulting decarboxylated phenolic acids have antioxidant and/or anti-inflammatory properties and can be used as ingredients in food and beverage products and to treat certain health conditions.Type: ApplicationFiled: March 12, 2009Publication date: February 24, 2011Applicant: NESTEC S.A.Inventors: Rachid Bel-Rhlid, Karin Kraehenbuehl, Christophe Cavin, Thomas Wolfgang Raab, Nicolas Page
-
Publication number: 20110039946Abstract: Disclosed is a method of improving atopic dermatological diseases, in which a composition comprising magnolol, honokiol or a combination thereof is administered to a patient with atopic dermatological diseases.Type: ApplicationFiled: October 21, 2010Publication date: February 17, 2011Applicant: BIOSPECTRUM, INC.Inventors: Deok Hoon PARK, Jong Sung LEE, Junho PARK, Eunsun JUNG, Seong Taek HONG
-
Publication number: 20110039945Abstract: The present invention relates to compositions, preferably in the form of a powder and/or granules, which contain resveratrol and pectin, and a process for the manufacture of such compositions.Type: ApplicationFiled: October 10, 2008Publication date: February 17, 2011Applicant: DSM IP ASSETS B.V.Inventors: Chyi-Cheng Chen, Sui-Kchen Chen, Sylvain Diguet, Bruno Leuenberger, Kai Urban
-
Publication number: 20110027230Abstract: Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-?, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia.Type: ApplicationFiled: February 20, 2009Publication date: February 3, 2011Inventors: Alfredo Di Leo, Michele Barone
-
Publication number: 20110021640Abstract: The present invention pertains to methods (a) Inhibition of adenosine deaminase by resveratrol products including botanical extracts containing resveratrol and/or oxyresveratrol; (b) Biochemical Standardization of these products as Enzyme Inhibitory Units (EIU) per mg or gram; and (c) Their uses thereof.Type: ApplicationFiled: July 26, 2010Publication date: January 27, 2011Inventor: Kailash Chandra Agarwal
-
Patent number: 7867523Abstract: A pharmaceutical composition for the treatment of colds and influenza. The pharmaceutical composition is a mixture of: acetaminophen, diphenhydramine, dextromethorphan, arabinogalactan, vitamin C, zinc, olive leaf extract, resveratrol and elderberry extract.Type: GrantFiled: July 18, 2008Date of Patent: January 11, 2011Inventor: Elaine A. Vanterpool
-
Publication number: 20110002905Abstract: The present invention relates to compositions containing one or more proteins, one or more polysaccharides and one or more fat-soluble active ingredients and their use for the enrichment, fortification and/or coloration of food beverages, animal feed and/or cosmetics.Type: ApplicationFiled: February 23, 2010Publication date: January 6, 2011Applicants: DSM IP ASSETS B.V., FUDAN UNIVERSITYInventors: Chyi-Cheng CHEN, Ping Yao, Bruno H. Leuenberger, Gerhard Wagner, Keke Xu, Shi-Kchen Chen
-
Publication number: 20100331391Abstract: In this application is described a novel, multiparameter analysis of TCR-coupled signaling and function in resting and activated naive and memory CD4 T cells, revealing a biochemical basis for immunological recall. Results reveal a novel biochemical signature imparted to memory CD4 T cells enabling efficacious responses through increased ZAP-70 expression and reduced accumulation of downstream signaling events.Type: ApplicationFiled: September 10, 2008Publication date: December 30, 2010Inventors: Meena Chandok, Donna Farber, Francesca Okoye
-
Publication number: 20100323979Abstract: The present invention relates, in part, to the use of AMP kinase agonists to reduce or inhibit the proliferation of aneuploid cells. The invention is also directed to the use AMP kinase agonists to reduce or inhibit the proliferation of solid tumors characterized by aneuploidy in an individual.Type: ApplicationFiled: June 16, 2010Publication date: December 23, 2010Inventors: Angelika B. Weis-Amon, Yun-Chi Tang
-
Publication number: 20100324149Abstract: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.Type: ApplicationFiled: July 26, 2010Publication date: December 23, 2010Inventor: Michael David
-
Publication number: 20100316679Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.Type: ApplicationFiled: January 7, 2010Publication date: December 16, 2010Applicants: President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: David A. Sinclair, Maria Alexander-Bridges
-
Publication number: 20100297040Abstract: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.Type: ApplicationFiled: April 2, 2010Publication date: November 25, 2010Inventor: Candace Rose Keefe
-
Publication number: 20100292345Abstract: The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.Type: ApplicationFiled: June 25, 2008Publication date: November 18, 2010Applicant: GW PHARMA LIMITEDInventor: Roger Pertwee
-
Publication number: 20100286095Abstract: A polyamine-depleted food compositions is provided for preparing foods, intended for humans or animals, for preventing or treating heart rate anomalies.Type: ApplicationFiled: January 10, 2007Publication date: November 11, 2010Inventors: Jacques Moulinoux, Jean-Pie'rre Estebe
-
Publication number: 20100273895Abstract: Described herein are pharmaceutical compositions comprising a cannabinoid, such as cannabidiol or a cannabidiol prodrug, which is metabolized to cannabidiol, and a penetration enhancer. Also described herein are methods of using the same. One embodiment described herein relates to the transdermal or topical administration of pharmaceutical compositions comprising a cannabinoid, such as cannabidiol or a cannabidiol prodrug, and a penetration enhancer to a person in need thereof.Type: ApplicationFiled: April 28, 2010Publication date: October 28, 2010Applicant: AllTranz Inc.Inventors: Audra Lynn Stinchcomb, Stan Lee Banks
-
Patent number: 7811996Abstract: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.Type: GrantFiled: November 1, 2002Date of Patent: October 12, 2010Assignee: The Regents of the University of CaliforniaInventor: Michael David
-
Publication number: 20100255103Abstract: A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of said plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.Type: ApplicationFiled: December 8, 2008Publication date: October 7, 2010Applicant: The Regents of the University of CaliforniaInventors: Monty Liong, Jie Lu, Fuyuhiko Tamanoi, Jeffrey I. Zink, Andre Nel
-
Publication number: 20100249223Abstract: The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel.Type: ApplicationFiled: April 17, 2008Publication date: September 30, 2010Applicant: GW Pharma LimitedInventors: Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello
-
Publication number: 20100247632Abstract: Methods and compositions are described whereby poorly water-soluble beneficial agents such as vitamins and co-factors are formulated into self-emulsifying formulas (SEF) and optionally sorbing the SEF into pores of porous solid particulates, or preparing supersaturated solutions (SSS) and sorbing the SSS into pores of porous solid particulates. These formulations are useful as dosage forms with oral availability.Type: ApplicationFiled: March 24, 2010Publication date: September 30, 2010Inventors: Liang C. DONG, Katrina Andrea U. Co, Shu Li, Crystal Pollock-Dove
-
Publication number: 20100239681Abstract: A pharmaceutical composition. The composition has a plurality of controlled release particulates. Each particulate includes a coating layer and a core partially coated with the coating layer, in which the core contains a water-insoluble drug 5-80 wt. % and a first polymer 0.2-80 wt. % and the coating layer contains the water-insoluble drug 0-50 wt. % and a second polymer 0.2-50 wt. %. Each of the first and second polymers, independently, is a water-insoluble polymer, an enteric polymer, or a combination thereof. A method of making the composition is also disclosed herein.Type: ApplicationFiled: March 20, 2009Publication date: September 23, 2010Applicant: Biokey, Inc.Inventors: David Wong, Xiufang Cheng, San-Laung Chow
-
Publication number: 20100239552Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: March 16, 2010Publication date: September 23, 2010Applicant: GENMEDICA THERAPEUTICS SLInventors: Eric Mayoux, Luc Marti Clauzel, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Alec Mian
-
Publication number: 20100239693Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.Type: ApplicationFiled: January 17, 2007Publication date: September 23, 2010Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Bettina Platt